Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

Winnie G. Vos, Esther Lutgens, Tom T.P. Seijkens

Research output: Contribution to journalArticlepeer-review

Abstract

In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.

Original languageEnglish (US)
Article numbere005611
JournalJournal for ImmunoTherapy of Cancer
Volume10
Issue number9
DOIs
StatePublished - Sep 2 2022

Keywords

  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?'. Together they form a unique fingerprint.

Cite this